Summary:
Healthy allogeneic donors, who were treated with G-CSF and underwent peripheral blood haematopoietic precursor collection at our Institution, were enrolled in a short- and long-term haematological surveillance protocol for a 5–7-year period. To date, 94 donors have been assessed with a mean follow-up of 30 months (4–84); for 30 subjects, the follow-up is ⩾48 months. During G-CSF administration, 23/94 donors showed a significant platelet count decrease from the baseline. Pre-apheresis platelet decrement correlated with the total G-CSF dose administered, baseline platelet level and donor age. Normal platelet counts returned within 4–8 months. PMN and/or lymphocyte lower values were observed in 55/94 donors 2 weeks after G-CSF administration, with mean drops from the baseline of 40 and 36% for PMN and lymphocytes, respectively. The PMN decrease correlated inversely with donor age, as younger donors were more affected than older ones, whereas the lymphocyte decrease correlated directly with the total blood volumes processed in the apheresis courses, in particular for donors subjected to large volume leukaphereses. Long-term observation showed moderate neutrophil reduction (25% count drop from the baseline) in four of the 30 donors observed for four years or more. 14 donors showed persistent, slight lymphocytopenia (mean drop of 13%) until the third year, with recovery in the fourth year of follow-up.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anderlini P, Przepiorka D, Champlin R, Korbling M . Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88: 2819–2825.
Cesaro S, Marson P, Gazzola MV et al. The use of cytokine-stimulated healthy donors in allogeneic stem cell transplantation. Haematologica 2002; 87: 35–41.
Korbling M, Champlin R . Peripheral blood progenitor stem transplantation: a replacement for marrow auto or allografts. Stem Cells 1996; 14: 185–195.
Kaplinsky C, Trakhtenbrot L, Hardan I et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31–34.
Makita K, Ohta K, Mugitani A et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661–665.
Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996; 36: 590–595.
Hilbe W, Nussbaumer W, Bonatti H et al. Unusual adverse effects following peripheral blood-stem cell (PBSC) mobilization using granulocyte colony-stimulating factor (G-CSF) in healthy donors. Bone Marrow Transplant 2000; 26: 811–813.
Adkins DR . Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor. J Clin Oncol 1998; 16: 812–813.
Stroncek D, Shawker T, Follmann D, Leitman SF . G-CSF induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43: 609–613.
Sakamaki S, Matsunaga T, Hirayama Y et al. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432–1433.
Cavallaro AM, Lilleby K, Majolino I et al. Three to six years of follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.
Stroncek DF, Clay ME, Herr G et al. Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997; 37: 304–308.
Anderlini P, Korbling M, Dale D et al. Allogeneic blood stem cell transplantation: consideration for donors. Blood 1997; 90: 903–908.
Stroncek D, McCullough J . Policies and procedures for the establishment of an allogeneic blood stem cell collection programme. Transfusion Med 1997; 7: 77–87.
Executive Committee of the World Marrrow Donor Association: Bone marrow transplant using volunteers donors. Recommendation and requirements for a standardized practice throughout the world. Bone Marrow Transplant 1992; 10: 287–293.
GITMO, IBMDR, SidE, SIE. Linee guida per la raccolta delle cellule staminali ai fini di un trapianto allogenico di midollo osseo. SIMTI servizi 2001.
Anderlini P, Przepiorka D, Seong D et al. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 1996; 94: 155–158.
Stroncek DF, Clay ME, Petzold ML et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and the collection of peripheral blood stem cells. Transfusion 1996; 36: 601–610.
Martinez C, Urbano-Ispizua A, Rozman M et al. Effects of short-term administration of G-CSF (Filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. Bone Marrow Transplant 1999; 23: 15–19.
Rutella S, Rumi C, Pierelli L et al. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp Hematol 2000; 28: 164–168.
Nagler A, Korenstein-Ilan A, Amiel A, Avivi A . Granulocyte-colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122–130.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tassi, C., Tazzari, P., Bonifazi, F. et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 36, 289–294 (2005). https://doi.org/10.1038/sj.bmt.1705066
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705066
Keywords
This article is cited by
-
Psychological and physical side effects during G-CSF mobilization in related donors of allo-HCT
Annals of Hematology (2024)
-
Cancer incidence in healthy Swedish peripheral blood stem cell donors
Bone Marrow Transplantation (2022)
-
G-CSF-primed BM for allogeneic SCT: revisited
Bone Marrow Transplantation (2015)
-
A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies
Bone Marrow Transplantation (2015)
-
Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)
Bone Marrow Transplantation (2013)